Small for Gestational Age 

• Genotropin^® is indicated for the treatment of growth disturbance in short children born SGA with a birth weight and/or length below −2 SD.^1,2
   
• Children classified as born SGA may have concurrent diagnoses such as familial short stature, TS or GHD. Approximately 10% of children born SGA do not reach the normal height range.¹

Study results: Effects of GH treatment on SGA children treated until reaching their final height

• Achieving catch-up growth and normalising final height³
   
• Increase in height following initiation of treatment with GH (0.033 mg/kg/day)³

Adapted from Dahlgren J, et al. 2005.³

Study methods³

Observational study of 77 prepubertal short children born SGA (−2 SD birth weight or length; mean age 10.7 years) in which patients received 0.033 mg/kg/day GH treatment until final height is reached (1 year after height velocity <1 cm/year). During puberty, 28 children were randomised to receive 66 μg/kg/day GH. Children were subdivided according to the duration of GH treatment before puberty (>2 years [n=36] and <2 years [n=41]). Growth response was compared with a comparison group of 34 untreated short prepubertal SGA children. The values are the means ± SE. Mid-parental height SD score.

Study findings

GH normalised final height in short children born SGA, allowing most patients (86%) to reach their target final height.³

Adverse events in the long-term treatment of children with growth disturbance due to born SGA (Clinical trials)²

Local product document, Somatropin 5.3 mg and 12 mg formulation, Genotropin : Version LPDGEN072022.